Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19094018 | TESTOSTERONE ENHANCING COMPOSITIONS AND METHODS | March 2025 | January 2026 | Allow | 10 | 2 | 0 | Yes | No |
| 19076524 | INHIBITION OF CANCER CELL VIABILITY | March 2025 | June 2025 | Allow | 3 | 0 | 0 | No | No |
| 19068391 | ORGANIC BIOMATERIAL FOR BONE AND JOINT REPLACEMENT | March 2025 | May 2025 | Allow | 2 | 0 | 0 | No | No |
| 19061465 | FORMULATIONS OF BENDAMUSTINE | February 2025 | May 2025 | Allow | 3 | 1 | 0 | No | No |
| 18980349 | MICROPARTICLE FORMULATIONS FOR INTRAVENOUS THERAPY AND METHODS FOR THEIR MANUFACTURE AND USE | December 2024 | September 2025 | Allow | 9 | 2 | 0 | No | No |
| 18923418 | CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAME | October 2024 | March 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18783428 | COMPOSITIONS CONTAINING CANNABINOID NANOPARTICLES | July 2024 | March 2026 | Allow | 19 | 0 | 0 | No | No |
| 18739378 | SOLVENT-BASED METHOD FOR MAKING NANOCOMPOSITE PHARMACEUTICAL MATERIAL | June 2024 | August 2024 | Allow | 2 | 0 | 0 | No | No |
| 18658338 | INTRADIALYTIC USE OF SODIUM NITRITE | May 2024 | January 2026 | Allow | 20 | 1 | 0 | No | No |
| 18646171 | FORMULATIONS OF BENDAMUSTINE | April 2024 | August 2024 | Allow | 4 | 1 | 0 | No | No |
| 18646329 | FORMULATIONS OF BENDAMUSTINE | April 2024 | April 2025 | Allow | 12 | 2 | 0 | No | No |
| 18637263 | COMPOSITIONS, FORMULATIONS AND METHODS FOR STIMULATING RESPIRATION | April 2024 | December 2025 | Abandon | 20 | 2 | 1 | Yes | No |
| 18630735 | METHOD FOR MANUFACTURING BONE-REGENERATION MATERIAL COMPRISING BIODEGRADABLE FIBERS BY USING ELECTROSPINNING METHOD | April 2024 | March 2026 | Allow | 23 | 0 | 0 | No | No |
| 18598402 | Devices for Treating Diseases and Conditions | March 2024 | May 2024 | Allow | 2 | 0 | 0 | Yes | No |
| 18599125 | METHOD OF TREATING DISEASES | March 2024 | January 2025 | Allow | 10 | 2 | 0 | Yes | No |
| 18599127 | METHOD OF TREATING DISEASES | March 2024 | January 2025 | Allow | 10 | 2 | 0 | No | No |
| 18444175 | ENHANCED IMMUNE RESPONSE UPON TREATMENT WITH NITRIC OXIDE | February 2024 | April 2025 | Abandon | 14 | 1 | 0 | No | No |
| 18427459 | CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAME | January 2024 | July 2024 | Allow | 6 | 1 | 0 | No | No |
| 18426704 | TREATING AND PREVENTING DISEASE WITH TMA AND TMAO LOWERING AGENTS | January 2024 | April 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18421265 | NITRIC OXIDE THERAPIES | January 2024 | January 2026 | Allow | 24 | 2 | 0 | No | No |
| 18580703 | BIOMIMETIC, REACTIVE OXYGEN SPECIES-DETONABLE NANOCLUSTERS FOR ANTIRESTENOTIC THERAPY | January 2024 | January 2026 | Allow | 24 | 1 | 0 | No | No |
| 18411482 | IMMUNISATION OF LARGE MAMMALS WITH LOW DOSES OF RNA | January 2024 | November 2025 | Allow | 22 | 0 | 0 | No | No |
| 18408463 | METHODS OF USE OF EMULSION FORMULATIONS OF APREPITANT | January 2024 | January 2025 | Allow | 13 | 2 | 0 | No | No |
| 18405512 | COMPOSITION USED FOR THERAPEUTIC TREATMENT OF SKIN DISEASE | January 2024 | April 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18391766 | 3D Printed Scaffold Structures and Methods of Fabrication | December 2023 | September 2025 | Allow | 21 | 2 | 1 | Yes | No |
| 18542954 | PHARMACEUTICAL COMPOSITION FOR NASAL DELIVERY | December 2023 | February 2025 | Allow | 14 | 1 | 1 | No | No |
| 18519530 | POLYMER PARTICLES FOR NEUTROPHIL INJURY | November 2023 | January 2025 | Allow | 13 | 1 | 0 | No | No |
| 18516480 | SELF-EMULSIFYING DRUG DELIVERY (SEDDS) FOR OPHTHALMIC DRUG DELIVERY | November 2023 | August 2025 | Abandon | 21 | 1 | 1 | No | No |
| 18514644 | METHOD OF TREATING DISEASES | November 2023 | December 2025 | Abandon | 24 | 1 | 0 | No | No |
| 18498259 | FORMULATIONS OF BENDAMUSTINE | October 2023 | October 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18556796 | COMPOSITIONS AND METHODS RELATED TO MEGAKARYOCYTE-DERIVED EXTRACELLULAR VESICLES FOR FANCONI ANEMIA | October 2023 | September 2025 | Allow | 23 | 0 | 0 | No | No |
| 18556173 | INHIBITION OF CRYSTALLIZATION AND/OR BIOFILM FORMATION ON AN INDWELLING URINARY CATHETER | October 2023 | March 2026 | Allow | 29 | 2 | 0 | Yes | No |
| 18373603 | Medical Implants And Methods Of Manufacture | September 2023 | August 2024 | Allow | 11 | 0 | 0 | No | No |
| 18367876 | COMPOSITIONS AND METHODS FOR PROMOTING CELLULAR METABOLIC FITNESS | September 2023 | February 2026 | Abandon | 29 | 2 | 0 | No | Yes |
| 18239715 | Nanoparticles Containing a Taxane and their Use | August 2023 | May 2025 | Allow | 20 | 1 | 0 | No | No |
| 18457210 | THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE | August 2023 | July 2025 | Abandon | 23 | 1 | 0 | No | No |
| 18453988 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OPHTHALMIC CONDITIONS | August 2023 | April 2025 | Allow | 20 | 1 | 1 | No | No |
| 18235817 | COMPOSITION FOR HYDRATION AND REDUCING THE EFFECTS OF ACOHOL | August 2023 | August 2025 | Allow | 24 | 0 | 0 | No | No |
| 18451593 | MINIMIZING AGGLOMERATION OF DRUG PARTICLE COATING MATERIAL DURING STORAGE TO STABILIZE DISINTEGRATION TIMES OF PHARMACEUTICAL PRODUCTS | August 2023 | April 2025 | Allow | 20 | 1 | 0 | No | No |
| 18448809 | MICROBIOLOGICAL TRANSPORT MEDIUM AND METHODS OF USING THE SAME | August 2023 | March 2025 | Abandon | 19 | 1 | 1 | No | No |
| 18362813 | METALLO-LIOTHYRONINE | July 2023 | February 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18224232 | BENDAMUSTINE SOLID DISPERSIONS AND CONTINUOUS INFUSION | July 2023 | May 2025 | Abandon | 22 | 1 | 1 | No | No |
| 18221143 | Powder Blend Processability Improvements Through Minimal Amounts Of Synergistically Selected Surface Coating Agents | July 2023 | April 2024 | Allow | 9 | 2 | 0 | Yes | No |
| 18219623 | ENCAPSULATED PROBIOTIC | July 2023 | June 2025 | Allow | 23 | 4 | 0 | No | No |
| 18267783 | USE OF TWO-DIMENSIONAL NANOMATERIAL IN INHIBITION OF CORONAVIRUS | June 2023 | February 2026 | Allow | 32 | 2 | 0 | No | No |
| 18329399 | INSOLUBLE TRANSDERMAL MICRONEEDLE PATCH, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | June 2023 | September 2023 | Allow | 3 | 0 | 0 | No | No |
| 18265066 | HOMOGENEOUS PHARMACEUTICAL EXCIPIENT SODIUM STEARYL FUMARATE WITH FLAKY STRUCTURE AND PREPARATION METHOD THEREOF | June 2023 | November 2025 | Allow | 29 | 1 | 0 | No | No |
| 18204728 | CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAME | June 2023 | October 2023 | Allow | 5 | 1 | 0 | No | No |
| 18322657 | Product and method for increasing uridine concentration in blood plasma | May 2023 | January 2026 | Abandon | 32 | 0 | 1 | No | No |
| 18313924 | SODIUM PERCARBONATE DISSOLVING BATH PRODUCT FORMULATION | May 2023 | October 2025 | Abandon | 29 | 2 | 1 | No | No |
| 18307184 | DEVICE POSITIONABLE IN THE UTERINE CAVITY AND METHOD OF TREATMENT THEREOF | April 2023 | July 2024 | Allow | 15 | 1 | 0 | No | No |
| 18302899 | COMPOSITIONS AND METHODS | April 2023 | March 2026 | Abandon | 35 | 0 | 1 | No | No |
| 18295863 | METHOD FOR FORMING A SILVER-CONTAINING NANOCOMPOSITE PHARMACEUTICAL COMPOUND | April 2023 | May 2024 | Allow | 14 | 0 | 0 | No | No |
| 18127862 | LIPOSOME ENCAPSULATING CYSTEAMINE AND RESVERATROL IN SEPARATE COMPARTMENTS | March 2023 | June 2025 | Abandon | 27 | 4 | 0 | No | No |
| 18127633 | PHARMACEUTICAL LOTION OR SALVE UTILIZING MIXED METAL HYDROXIDE ANTIMICROBIAL CHARGED PARTICLES | March 2023 | August 2023 | Allow | 4 | 1 | 0 | Yes | No |
| 18190839 | SOLUTION FOR ORAL ADMINISTRATION | March 2023 | October 2024 | Abandon | 18 | 1 | 0 | No | No |
| 18186304 | METHOD OF TREATING SPINAL DISK | March 2023 | July 2024 | Allow | 16 | 1 | 0 | No | No |
| 18185689 | COMPOSITIONS AND METHODS FOR PREVENTING AND/OR AMELIORATING ORGAN-SPECIFIC AUTOIMMUNE DISEASES | March 2023 | January 2026 | Abandon | 34 | 1 | 0 | No | No |
| 18120762 | Lyophilized Formulations of AAV Drug Products | March 2023 | February 2026 | Allow | 35 | 1 | 1 | No | No |
| 18044969 | METHODS FOR PREPARATION OF A TERMINALLY STERILIZED HYDROGEL OR COLLOIDAL SUSPENSION DERIVED FROM EXTRACELLULAR MATRIX, AND USES THEREOF | March 2023 | January 2026 | Allow | 34 | 1 | 0 | No | No |
| 18115789 | ANTIBACTERIAL SURFACE OF METAL-ORGANIC FRAMEWORK-CHITOSAN COMPOSITE FILMS | March 2023 | February 2025 | Allow | 23 | 2 | 0 | Yes | No |
| 18174549 | OXYGEN-CONTAINING PARTICLES, MANUFACTURING METHOD THEREFOR, AND USE THEREOF | February 2023 | December 2025 | Abandon | 34 | 1 | 0 | No | No |
| 18022193 | COMPOUNDS FOR PREVENTION OR TREATMENT OF NEURODEGENERATIVE DISORDERS | February 2023 | July 2025 | Allow | 29 | 0 | 0 | No | No |
| 18092569 | INTRADIALYTIC USE OF SODIUM NITRITE | January 2023 | February 2024 | Allow | 13 | 0 | 0 | Yes | No |
| 18086506 | METHOD OF MANUFACTURING A BIOIMPLANT | December 2022 | October 2024 | Allow | 22 | 2 | 0 | Yes | No |
| 18081238 | FORMULATIONS OF BENDAMUSTINE | December 2022 | October 2023 | Allow | 10 | 3 | 0 | Yes | No |
| 18081251 | FORMULATIONS OF BENDAMUSTINE | December 2022 | November 2023 | Allow | 11 | 3 | 0 | Yes | No |
| 18072473 | CENTANAFADINE PHARMACEUTICAL FORMULATIONS, AND METHODS OF MAKING AND USING SAME | November 2022 | July 2023 | Allow | 8 | 1 | 0 | No | No |
| 18070134 | METHOCARBAMOL COMPOSITIONS AND RELATED METHODS | November 2022 | July 2024 | Allow | 20 | 1 | 0 | No | No |
| 17999870 | METHODS OF TREATMENT OF VIRAL DISEASES | November 2022 | December 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17991157 | METHODS OF PRODUCING AN OSTEOINDUCTIVE CALCIUM PHOSPHATE MATERIAL FOR BONE GRAFTING | November 2022 | July 2024 | Abandon | 20 | 1 | 0 | No | No |
| 17999194 | CGAS INHIBITING TRIAZOLOPYRIMIDONE DERIVATIVES | November 2022 | August 2025 | Allow | 33 | 1 | 0 | No | No |
| 17987989 | DEVICES AND METHODS FOR DELIVERY OF SUBSTANCES TO ANIMALS | November 2022 | May 2024 | Allow | 18 | 1 | 1 | Yes | No |
| 17987983 | DEVICES AND METHODS FOR DELIVERY OF SUBSTANCES TO ANIMALS | November 2022 | October 2024 | Allow | 23 | 3 | 1 | Yes | No |
| 18054082 | POLYMER LUNG SURFACTANTS | November 2022 | July 2025 | Allow | 32 | 3 | 0 | No | No |
| 17978700 | Method for Coating Pharmaceutical Substrates | November 2022 | December 2023 | Allow | 14 | 3 | 0 | Yes | No |
| 17922223 | CRYSTAL OF TRIFLUOROMETHYL/CHLORO DISUBSTITUTED SULFONAMIDE SELECTIVE BCL-2 INHIBITOR | October 2022 | October 2025 | Allow | 36 | 1 | 0 | No | No |
| 17972172 | Pharmaceutical Formulation with Improved Solubility and Bioavailability | October 2022 | May 2025 | Allow | 31 | 3 | 0 | No | No |
| 17966092 | IMPLANTS INCLUDING MODIFIED DEMINERALIZED CORTICAL BONE FIBERS AND METHODS OF MAKING SAME | October 2022 | December 2024 | Allow | 26 | 2 | 0 | No | No |
| 17965209 | CERAMIC COMPOSITION COMPRISING ANTIMICROBIAL GLASS COMPOSITION | October 2022 | November 2025 | Allow | 37 | 3 | 0 | No | No |
| 18045377 | SYSTEMS AND METHODS TO REPAIR TISSUE DEFECTS | October 2022 | January 2025 | Allow | 27 | 3 | 0 | Yes | No |
| 17962381 | COMPOSITIONS AND METHODS FOR PROMOTING CELLULAR METABOLIC FITNESS | October 2022 | January 2024 | Abandon | 16 | 2 | 1 | Yes | No |
| 17914587 | THERAPEUTIC STRATEGIES TO MANAGE FACIAL CONTRACTURES POST INJURY | September 2022 | December 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17945618 | MOLDABLE ORTHOPEDIC COMPOSITION WITH ANTI-WASHOUT PROPERTY | September 2022 | January 2026 | Allow | 40 | 1 | 0 | No | No |
| 17930716 | Zeaxanthin Formulations With Additional Ocular-Active Nutrients, For Protecting Eye Health And Treating Eye Disorders | September 2022 | December 2023 | Abandon | 16 | 2 | 0 | Yes | Yes |
| 17901258 | Cartilage Regeneration Using Injectable, In Situ Polymerizable Collagen Compositions Containing Chondrocytes or Stem Cells | September 2022 | October 2023 | Allow | 14 | 2 | 1 | No | No |
| 17895347 | SOLID DELTA9-TETRAHYDROCANNABINOL (DELTA9-THC) COMPOSITIONS | August 2022 | May 2024 | Allow | 21 | 1 | 0 | No | No |
| 17819934 | METHOD FOR PRODUCING A DRUG DELIVERY SYSTEM | August 2022 | January 2025 | Allow | 29 | 2 | 0 | No | No |
| 17819675 | CELLULAR BONE GRAFTS, AND METHODS OF MANUFACTURE AND USE | August 2022 | November 2024 | Allow | 27 | 3 | 0 | No | No |
| 17819942 | METHOD FOR PRODUCING A DRUG DELIVERY SYSTEM | August 2022 | January 2025 | Allow | 30 | 2 | 0 | No | No |
| 17819941 | METHOD FOR PRODUCING A DRUG DELIVERY SYSTEM | August 2022 | January 2025 | Allow | 30 | 2 | 0 | No | No |
| 17819940 | METHOD FOR PRODUCING A DRUG DELIVERY SYSTEM | August 2022 | January 2025 | Allow | 29 | 2 | 0 | No | No |
| 17819938 | METHOD FOR PRODUCING A DRUG DELIVERY SYSTEM | August 2022 | January 2025 | Allow | 29 | 2 | 0 | No | No |
| 17879557 | METHOD OF TREATING DISEASES | August 2022 | October 2022 | Allow | 2 | 1 | 0 | No | No |
| 17803470 | Processes for Breaching Blood-Brain Barrier | July 2022 | January 2024 | Abandon | 18 | 1 | 0 | No | No |
| 17859820 | SHAPE CHANGING DRUG DELIVERY DEVICES AND METHODS | July 2022 | December 2023 | Allow | 17 | 0 | 0 | Yes | No |
| 17858404 | NOVEL PHARMACEUTICAL FORMULATIONS CONTAINING INDIRUBIN AND DERIVATIVES THEREOF AND METHODS OF MAKING AND USING THE SAME | July 2022 | February 2025 | Abandon | 31 | 2 | 1 | No | No |
| 17428273 | A CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION OF SELEXIPAG OR IT'S ACTIVE METABOLITE | July 2022 | July 2025 | Allow | 48 | 2 | 0 | Yes | No |
| 17808390 | PHARMACEUTICAL COMPOSITION COMPRISING A POTENT INHIBITOR OF URAT1 | June 2022 | March 2024 | Abandon | 21 | 1 | 0 | No | No |
| 17840002 | PHARMACEUTICAL COMPOSITIONS COMPRISING ZINC | June 2022 | April 2024 | Abandon | 22 | 1 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ARNOLD, ERNST V.
With a 17.7% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 10.5% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner ARNOLD, ERNST V works in Art Unit 1613 and has examined 1,237 patent applications in our dataset. With an allowance rate of 51.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 30 months.
Examiner ARNOLD, ERNST V's allowance rate of 51.3% places them in the 13% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by ARNOLD, ERNST V receive 2.44 office actions before reaching final disposition. This places the examiner in the 71% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.
The median time to disposition (half-life) for applications examined by ARNOLD, ERNST V is 30 months. This places the examiner in the 58% percentile for prosecution speed. Prosecution timelines are slightly faster than average with this examiner.
Conducting an examiner interview provides a +11.4% benefit to allowance rate for applications examined by ARNOLD, ERNST V. This interview benefit is in the 46% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 14.4% of applications are subsequently allowed. This success rate is in the 10% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 29.5% of cases where such amendments are filed. This entry rate is in the 42% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 23.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 28% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 45.1% of appeals filed. This is in the 11% percentile among all examiners. Of these withdrawals, 54.9% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner rarely withdraws rejections during the appeal process compared to other examiners. If you file an appeal, be prepared to fully prosecute it to a PTAB decision. Per MPEP § 1207, the examiner will prepare an Examiner's Answer maintaining the rejections.
When applicants file petitions regarding this examiner's actions, 56.1% are granted (fully or in part). This grant rate is in the 58% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.9% of allowed cases (in the 66% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.9% of allowed cases (in the 60% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.